5-氯-4-氟-2-硝基苯甲酸甲酯 | 623588-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氯-4-氟-2-硝基苯甲酸甲酯
• 英文名称: methyl 5-chloro-4-fluoro-2-nitro-benzoate
• 英文别名: Methyl 5-chloro-4-fluoro-2-nitrobenzoate
• CAS: 623588-40-9
• 化学式: C₈H₅ClFNO₄
• 分子量: 233.583
• InChiKey: LFDJJFPADBUPQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-氯-4-氟-2-硝基苯甲酸甲酯 在 palladium 10% on activated carbon ammonium formate 作用下， 以 水 、 异丙醇 为溶剂， 反应 3.0h， 以97.8%的产率得到2-氨基-4-氟苯甲酸甲酯
  参考文献：
  名称：

  [EN] PROCESS FOR THE MANUFACTURE OF 4-FLUORO-ANTHRANILIC ACID
  [FR] PROCEDE DE FABRICATION D'ACIDE 4-FLUORO-ANTHRANILIQUE

  摘要：

  本发明涉及一种通过对烷基3-氯-4-氟苯甲酸酯进行硝化、还原和水解制备4-氟基蒽酸的方法。

  公开号：

  WO2003095417A1
• 作为产物：
  描述：

  3-氯-4-氟苯甲酸甲酯 在 硫酸 、 硝酸 作用下， 以 硫酸 为溶剂， 以85.11%的产率得到5-氯-4-氟-2-硝基苯甲酸甲酯
  参考文献：
  名称：

  [EN] PROCESS FOR THE MANUFACTURE OF 4-FLUORO-ANTHRANILIC ACID
  [FR] PROCEDE DE FABRICATION D'ACIDE 4-FLUORO-ANTHRANILIQUE

  摘要：

  本发明涉及一种通过对烷基3-氯-4-氟苯甲酸酯进行硝化、还原和水解制备4-氟基蒽酸的方法。

  公开号：

  WO2003095417A1

文献信息

• [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO
  申请人：Scarborough Robert

  公开号：US20070123547A1

  公开（公告）日：2007-05-31

  The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了式（I）的新型磺酰脲化合物及其药学上可接受的衍生物、多晶型和非晶态形式。这些化合物在其各种形式下是有效的血小板ADP受体抑制剂，可用于各种制药组合物中，并且特别有效于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。本发明还提供了一种制备这样的化合物和形式以及在哺乳动物中预防或治疗血栓形成和与血栓形成有关的疾病的方法，包括给予式（I）的化合物或其药学上可接受的盐或形式的治疗有效量。
• [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO
  申请人：Sharp Emma

  公开号：US20090042916A1

  公开（公告）日：2009-02-12

  The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.

  本发明提供了一种盐酸式(I)盐的磺酰脲盐及其多晶形式。这些化合物在其各种形式下都是有效的血小板ADP受体抑制剂，可用于各种药物组合物中，并且特别有效用于预防和/或治疗心血管疾病，特别是与血栓相关的疾病。本发明还提供了一种制备这些化合物和形式以及在哺乳动物中预防或治疗血栓和与血栓相关疾病的方法，包括给予公式(I)的盐或其药学上可接受的形式的治疗有效量。
• [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto
  申请人：Scarborough Robert

  公开号：US20120088736A1

  公开（公告）日：2012-04-12

  The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了式（I）的新型磺酰脲化合物及其药学上可接受的衍生物、多晶形式和非晶形式。这些化合物在其各种形式下均为有效的血小板ADP受体抑制剂，可用于各种制药组合物中，并且特别有效于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病。本发明还提供了制备这些化合物和形式的方法，并用于在哺乳动物中预防或治疗血栓形成和与血栓形成相关的疾病，包括给予式（I）化合物或其药学上可接受的盐或形式的治疗有效量。
• [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
  申请人：Portola Pharmaceuticals, Inc.

  公开号：EP2428514A1

  公开（公告）日：2012-03-14

  The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

  本发明提供了新颖的式(I)磺酰脲化合物和药学上可接受的衍生物及其多晶型和无定形型。这些化合物的各种形式是有效的血小板 ADP 受体抑制剂，可用于各种药物组合物中，对预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病特别有效。本发明还提供了一种制备此类化合物和形式以及预防或治疗哺乳动物血栓形成和血栓形成相关疾病的方法，包括施用治疗有效量的式(I)化合物或其药学上可接受的盐或形式的步骤。
• EP1951254A4
  申请人：——

  公开号：EP1951254A4

  公开（公告）日：2009-05-27